Serum atrial natriuretic peptide: a suspected biomarker of breast cancer

Maha E. Houssen; Hayam F. Ghazy; Kamel Farag; Mona Abo Bakr El-Hussiny; Mohamed A. El Ghaffar; Sahar Alsayed Mohamed Alsayed; Omar Farouk

doi:10.5114/wo.2017.66657

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2017
vol. 21

Send email

Copy url:

abstract:

Original paper

Serum atrial natriuretic peptide: a suspected biomarker of breast cancer

Maha E. Houssen

,

Hayam F. Ghazy

,

Kamel Farag

,

Mona Abo Bakr El-Hussiny

,

Mohamed A. El Ghaffar

,

Sahar Alsayed Mohamed Alsayed

,

Omar Farouk

Contemp Oncol (Pozn) 2017; 21 (1): 54-59

DOI: https://doi.org/10.5114/wo.2017.66657

Online publish date: 2017/03/22

View full text Get citation

PlumX metrics:

Aim of the study: To assess serum levels of ANP in breast cancer female patients and its relationship to metastasis and some clinical parameters among those patients.

Material and methods: One hundred breast cancer patients with and without metastasis along with 20 healthy closely matched controls, were enrolled in the present cross sectional study. Background: To assess the serum levels of atrial natriuretic peptide in breast cancer Serum levels of ANP were assessed using ELISA.

Results: Mean serum levels of ANP breast cancer patients (13.9 ±10.1 ng/ml) were significantly elevated compared to healthy control group (2.2 ±1.3 ng/ml) (p < 0.001). The metastatic breast cancer patients showed significant elevated ANP levels (17.1 ±8.9 ng/ml) compared to non-metastatic group (6.4 ±8.8 ng/ml) p < 0.001. Within the metastatic group significant difference was detected between de novo metastatic, under follow-up, under hormonal control and locally advanced group (p = 0.007).

Conclusions: This study showed significant elevated levels of ANP in the serum of metastatic breast cancer patients compared to non-metastatic patients. Within the metastatic group the lowest levels were detected in metastatic breast Cancer under hormonal treatment either tamoxifen or aromatase inhibitor.

keywords:

Serum atrial natriuretic peptide: a suspected biomarker of breast cancer

Maha E. Houssen , Hayam F. Ghazy , Kamel Farag , Mona Abo Bakr El-Hussiny , Mohamed A. El Ghaffar , Sahar Alsayed Mohamed Alsayed , Omar Farouk

atrial natriuretic peptide, breast cancer, metastases

Maha E. Houssen

,

Hayam F. Ghazy

,

Kamel Farag

,

Mona Abo Bakr El-Hussiny

,

Mohamed A. El Ghaffar

,

Sahar Alsayed Mohamed Alsayed

,

Omar Farouk